Surprising Analyst 12-Month Target For PABU
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 30 2025
0mins
Source: NASDAQ.COM
ETF Performance Analysis: The iShares Paris-Aligned Climate MSCI USA ETF (PABU) has an implied analyst target price of $74.02, indicating a potential upside of 12.66% from its current trading price of $65.70.
Stock Specific Upside Potential: Notable underlying holdings like Healthpeak Properties Inc, AMETEK Inc, and The Trade Desk Inc show significant upside potential based on average analyst target prices, raising questions about the validity of these targets amidst market developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DOC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DOC
Wall Street analysts forecast DOC stock price to rise
12 Analyst Rating
6 Buy
6 Hold
0 Sell
Moderate Buy
Current: 16.700
Low
16.71
Averages
19.23
High
21.00
Current: 16.700
Low
16.71
Averages
19.23
High
21.00
About DOC
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT). The Company acquires, develops, owns, leases, and manages healthcare real estate across the United States. It owns, operates, and develops real estate focused on healthcare discovery and delivery. The Company’s segments include Lab, Outpatient medical and continuing care retirement community (CCRC). The Outpatient medical segment owns, operates, and develops outpatient medical buildings, hospitals, and lab buildings. The lab segment properties contain laboratory and office space, are leased primarily to biotechnology, medical device and pharmaceutical companies, scientific research institutions, government agencies, and other organizations involved in the life science industry. Its CCRC segment is a retirement community that include independent living, assisted living, memory care, and skilled nursing units to provide a continuum of care in an integrated campus.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthpeak Secures $400 Million Loan to Enhance Liquidity
- Loan Financing Enhances Liquidity: Healthpeak Properties announced the successful closure of a $400 million unsecured delayed-draw term loan aimed at improving the company's liquidity and financial flexibility, thereby further strengthening its balance sheet.
- Loan Terms Details: The term loan matures in March 2031, with an interest rate of SOFR plus 80 basis points based on Healthpeak's current credit ratings, indicating the company's strong creditworthiness in securing financing.
- Bank Support and Confidence: CFO Kelvin Moses expressed gratitude for the continued support from the bank group and their confidence in Healthpeak, which not only reflects the company's market position but also provides funding assurance for future expansions.
- Loan Arranging Institutions: The unsecured term loan was arranged by BofA Securities, JPMorgan, and Wells Fargo Securities as joint bookrunners, showcasing the trust and support from major financial institutions towards Healthpeak.
See More
Janus Living Successfully IPOs, Raising Approximately $731 Million
- Successful IPO: Janus Living successfully closed the initial public offering of 48.3 million shares of Class A-1 common stock, including the full exercise of an overallotment option for an additional 6.3 million shares at $20 per share, raising approximately $731 million to strengthen its capital base for future acquisitions and investments.
- Clear Use of Proceeds: The company indicated that the net proceeds will be used to pursue acquisition and investment opportunities that meet its investment criteria, as well as for general corporate purposes, reflecting its proactive stance towards business expansion.
- Enhanced Credit Facilities: Janus Living also closed a new $500 million unsecured revolving credit facility and a $100 million unsecured delayed-draw term loan, enhancing its financial flexibility, with the revolving facility maturing in March 2030 and the term loan maturing in March 2031.
- Strong Liquidity Position: As of March 23, 2026, Janus Living reported total liquidity of approximately $1.5 billion, demonstrating its robust financial strength in the market, which supports future growth and investment plans.
See More
Analysis of High Dividend Yield Stocks
- Campbell's Company Performance: Campbell's Company (CPB) has seen its stock price drop by 41% over the past year, raising its dividend yield to 7.4%; despite challenges from inflation and tempered growth expectations, it maintains industry-leading market share across key brands.
- Healthpeak Properties Outlook: Healthpeak Properties (DOC), a real estate investment trust, has experienced a 7% decline in stock price over the past year, pushing its dividend yield up to 6.9%, with its focus on healthcare buildings and the upcoming spin-off of Janus Living providing potential for future growth.
- Kraft Heinz Investment Opportunity: Kraft Heinz (KHC) has seen a 22% drop in stock price over the past year, resulting in a dividend yield of 7.4%; despite challenges, the company is investing $600 million to refresh its brands and commercial capabilities, with the new CEO prioritizing profitable growth.
- Attractiveness of Dividend Yields: While these high-dividend stocks face individual challenges, their appeal lies in providing stable cash flow, allowing investors to enjoy generous dividends while waiting for company turnarounds.
See More
Healthcare Stocks Sell Off Amid Middle East Turmoil
- Reasons for Sell-Off: Healthcare stocks are experiencing a sell-off due to turbulence in the Middle East, despite typically being resilient during global uncertainties; the sector has been weighed down for months by Medicaid cuts and pharmaceutical tariffs, impacting investor confidence.
- Pfizer's Outlook: Pfizer (PFE) shares are currently worth half of their value from 2021, facing a patent cliff that could affect $17 billion in annual revenue by 2030; while the company is pursuing new drug developments through acquisitions, it still grapples with declining COVID drug sales in the short term.
- Alexandria Real Estate's Performance: Alexandria Real Estate Equities (ARE) has seen its stock plummet nearly 75% since its 2022 peak, primarily due to rising interest rates and an oversupply of lab space; although it is leasing to tech companies to offset demand issues, it still faces ongoing financial pressures and plans to cut its dividend by 45%.
- Healthpeak Properties IPO Plans: Healthpeak Properties (DOC) is set to launch an IPO for its senior housing portfolio, which will expose it to greater market risks despite retaining a majority stake; currently, its dividend coverage is slightly above 70%, but the company must demonstrate recovery potential in the life sciences sector.
See More
Janus Living Prices Upsized IPO at $20 per Share
- IPO Pricing: Janus Living has priced its upsized initial public offering at $20 per share for 42 million shares, aiming to raise approximately $731 million, reflecting strong market confidence in its business model and investor interest.
- Underwriter Option: The company has granted underwriters a 30-day option to purchase an additional 6.3 million shares at the IPO price, enhancing the offering's flexibility and market appeal.
- Trading Timeline: Janus Living's shares are expected to begin trading on the New York Stock Exchange on March 20, 2026, under the ticker symbol “JAN,” providing investors with a clear timeline for participation in the new stock.
- Ownership Structure: Following the IPO, Healthpeak Properties will own approximately 214.73 million shares of Janus Living, representing an 83.6% voting interest, indicating Healthpeak's strong control and strategic position in the market.
See More
Janus Living Prices Upsized IPO at $20 per Share
- IPO Pricing: Janus Living has priced its upsized initial public offering (IPO) at $20.00 per share for 42,000,000 shares, indicating strong market demand for its high-quality senior housing REIT, which is expected to generate significant capital inflow for the company.
- Underwriter Selection: BofA Securities and J.P. Morgan are acting as lead underwriters for the IPO, with several other prominent financial institutions involved, reflecting broad market recognition and confidence in the offering, which may enhance investor interest in the company.
- Equity Structure: After the IPO, Healthpeak will own approximately 214,734,000 shares of Janus Living, representing about 83.6% voting interest, ensuring its dominant position in company decisions and further solidifying its strategic positioning in the senior housing market.
- Use of Proceeds: Janus Living plans to utilize the net proceeds from the IPO for acquisition and investment opportunities that meet its investment criteria, which will help the company expand its high-quality communities across the U.S., enhancing its competitive edge and long-term growth potential.
See More
Healthpeak Secures $400 Million Loan to Enhance Liquidity
- Loan Financing Enhances Liquidity: Healthpeak Properties announced the successful closure of a $400 million unsecured delayed-draw term loan aimed at improving the company's liquidity and financial flexibility, thereby further strengthening its balance sheet.
- Loan Terms Details: The term loan matures in March 2031, with an interest rate of SOFR plus 80 basis points based on Healthpeak's current credit ratings, indicating the company's strong creditworthiness in securing financing.
- Bank Support and Confidence: CFO Kelvin Moses expressed gratitude for the continued support from the bank group and their confidence in Healthpeak, which not only reflects the company's market position but also provides funding assurance for future expansions.
- Loan Arranging Institutions: The unsecured term loan was arranged by BofA Securities, JPMorgan, and Wells Fargo Securities as joint bookrunners, showcasing the trust and support from major financial institutions towards Healthpeak.
See More
Janus Living Successfully IPOs, Raising Approximately $731 Million
- Successful IPO: Janus Living successfully closed the initial public offering of 48.3 million shares of Class A-1 common stock, including the full exercise of an overallotment option for an additional 6.3 million shares at $20 per share, raising approximately $731 million to strengthen its capital base for future acquisitions and investments.
- Clear Use of Proceeds: The company indicated that the net proceeds will be used to pursue acquisition and investment opportunities that meet its investment criteria, as well as for general corporate purposes, reflecting its proactive stance towards business expansion.
- Enhanced Credit Facilities: Janus Living also closed a new $500 million unsecured revolving credit facility and a $100 million unsecured delayed-draw term loan, enhancing its financial flexibility, with the revolving facility maturing in March 2030 and the term loan maturing in March 2031.
- Strong Liquidity Position: As of March 23, 2026, Janus Living reported total liquidity of approximately $1.5 billion, demonstrating its robust financial strength in the market, which supports future growth and investment plans.
See More
Analysis of High Dividend Yield Stocks
- Campbell's Company Performance: Campbell's Company (CPB) has seen its stock price drop by 41% over the past year, raising its dividend yield to 7.4%; despite challenges from inflation and tempered growth expectations, it maintains industry-leading market share across key brands.
- Healthpeak Properties Outlook: Healthpeak Properties (DOC), a real estate investment trust, has experienced a 7% decline in stock price over the past year, pushing its dividend yield up to 6.9%, with its focus on healthcare buildings and the upcoming spin-off of Janus Living providing potential for future growth.
- Kraft Heinz Investment Opportunity: Kraft Heinz (KHC) has seen a 22% drop in stock price over the past year, resulting in a dividend yield of 7.4%; despite challenges, the company is investing $600 million to refresh its brands and commercial capabilities, with the new CEO prioritizing profitable growth.
- Attractiveness of Dividend Yields: While these high-dividend stocks face individual challenges, their appeal lies in providing stable cash flow, allowing investors to enjoy generous dividends while waiting for company turnarounds.
See More
Healthcare Stocks Sell Off Amid Middle East Turmoil
- Reasons for Sell-Off: Healthcare stocks are experiencing a sell-off due to turbulence in the Middle East, despite typically being resilient during global uncertainties; the sector has been weighed down for months by Medicaid cuts and pharmaceutical tariffs, impacting investor confidence.
- Pfizer's Outlook: Pfizer (PFE) shares are currently worth half of their value from 2021, facing a patent cliff that could affect $17 billion in annual revenue by 2030; while the company is pursuing new drug developments through acquisitions, it still grapples with declining COVID drug sales in the short term.
- Alexandria Real Estate's Performance: Alexandria Real Estate Equities (ARE) has seen its stock plummet nearly 75% since its 2022 peak, primarily due to rising interest rates and an oversupply of lab space; although it is leasing to tech companies to offset demand issues, it still faces ongoing financial pressures and plans to cut its dividend by 45%.
- Healthpeak Properties IPO Plans: Healthpeak Properties (DOC) is set to launch an IPO for its senior housing portfolio, which will expose it to greater market risks despite retaining a majority stake; currently, its dividend coverage is slightly above 70%, but the company must demonstrate recovery potential in the life sciences sector.
See More
Janus Living Prices Upsized IPO at $20 per Share
- IPO Pricing: Janus Living has priced its upsized initial public offering at $20 per share for 42 million shares, aiming to raise approximately $731 million, reflecting strong market confidence in its business model and investor interest.
- Underwriter Option: The company has granted underwriters a 30-day option to purchase an additional 6.3 million shares at the IPO price, enhancing the offering's flexibility and market appeal.
- Trading Timeline: Janus Living's shares are expected to begin trading on the New York Stock Exchange on March 20, 2026, under the ticker symbol “JAN,” providing investors with a clear timeline for participation in the new stock.
- Ownership Structure: Following the IPO, Healthpeak Properties will own approximately 214.73 million shares of Janus Living, representing an 83.6% voting interest, indicating Healthpeak's strong control and strategic position in the market.
See More
Janus Living Prices Upsized IPO at $20 per Share
- IPO Pricing: Janus Living has priced its upsized initial public offering (IPO) at $20.00 per share for 42,000,000 shares, indicating strong market demand for its high-quality senior housing REIT, which is expected to generate significant capital inflow for the company.
- Underwriter Selection: BofA Securities and J.P. Morgan are acting as lead underwriters for the IPO, with several other prominent financial institutions involved, reflecting broad market recognition and confidence in the offering, which may enhance investor interest in the company.
- Equity Structure: After the IPO, Healthpeak will own approximately 214,734,000 shares of Janus Living, representing about 83.6% voting interest, ensuring its dominant position in company decisions and further solidifying its strategic positioning in the senior housing market.
- Use of Proceeds: Janus Living plans to utilize the net proceeds from the IPO for acquisition and investment opportunities that meet its investment criteria, which will help the company expand its high-quality communities across the U.S., enhancing its competitive edge and long-term growth potential.
See More
